Holen Sie sich die Stockscreener-App
6.20
1.97%
0.12
Schlusskurs vom Vortag:
$6.08
Offen:
$6.1
24-Stunden-Volumen:
444.98K
Relative Volume:
0.89
Marktkapitalisierung:
$133.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-4.00
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
-7.32%
1M Leistung:
+2.82%
6M Leistung:
+40.59%
1J Leistung:
+1,007%
1-Tages-Spanne:
$6.08
$6.25
1-Wochen-Bereich:
$5.98
$6.69
52-Wochen-Spanne:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.20 | 130.67M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics Doubles Stock Sale Agreement - MSN
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com
UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance of - GlobeNewswire
FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat
Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
2026-01-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Portfolio Shifts: Is VRAX a top pick in the sectorJuly 2025 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon - simplywall.st
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (NASDAQ:UNCY) Trading 1% HigherShould You Buy? - MarketBeat
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Fast Moving Trade Plans - ulpravda.ru
Can Unicycive Therapeutics Inc. stock continue upward trendQuarterly Portfolio Review & Capital Efficiency Focused Ideas - Улправда
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
News | Unicycive Therapeutics leases Mountain View offices - CoStar
How interest rate cuts could boost Unicycive Therapeutics Inc. stockMarket Trend Summary & Consistent Profit Trading Strategies - Улправда
How geopolitical tensions affect Unicycive Therapeutics Inc. stockBull Market Opportunities & Minimal Capital Investment - ulpravda.ru
Unicycive Therapeutics : January 2026 Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
UNCY Stock Price, Forecast & Analysis | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - Chartmill
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - marketscreener.com
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - MarketScreener
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):